Controlling Inflammation to Stop Disease
March 24, 2021 at 09:05 AM EDT
NetworkNewsWire Editorial Coverage: In a natural response to injury or infection, the body produces chemicals that trigger the immune system to release antibodies and proteins plus increase blood flow to the afflicted area, which aids healing and produces inflammation. However, the immune system and the inflammatory processes have pernicious aspects far removed from beneficial healing. In fact, inflammation has been directly linked to a wide variety of physical and mental health maladies. Inflammation is also a symptom of infectious diseases, implicated in noninfectious diseases, and new findings show a causal relationship with postsurgical trauma. Inflammatory diseases are recognized as the most significant cause of death in the world, with more than 50% of all deaths attributed to inflammation-related diseases. The recognition of the connection between inflammation and disease sparked a flurry of biotech research and a new generation of drug development to treat previously untreatable disorders. World renowned scientists that now lead 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Profile) pioneered the research and development of one of the first anti-inflammatory therapeutics to ever reach market, and today these drugs generate multiple billions of dollars in annual sales. Critical to creation of some the most important and profitable drugs ever on the market, the 180 team is in hot pursuit of new anti-inflammatory blockbusters with active programs in both preclinical and clinical studies. The world’s largest and most broadly based health-care company, Johnson & Johnson (NYSE: JNJ), owns Remicade (infliximab), a blockbuster several times over with approved use in a range of inflammatory diseases. The founders of 180 Life Sciences discovered the anti-TNF (tumor necrosis factor) drug class that led to the development of Remicade and to a $4.9 billion merger between JNJ and Centocor Biotech. AbbVie Inc. (NYSE: ABBV) owns Humira, an anti-TNF therapeutic and top-selling drug in the world. The scientists at 180 Life Sciences licensed the anti-TNF technology in development of Humira. One of the world’s leading biotech’s, Amgen Inc. (NASDAQ: AMGN), bought Celgene’s blockbuster anti-inflammatory drug Otezla in 2019 for $13.4 billion in cash, and Eli Lilly (NYSE: LLY) recently announced a deal for Rigel Pharmaceuticals’ autoimmune and inflammatory diseases treatment for $960 million. In addition to delivering much-needed relief for previously untreatable maladies, eye-popping sales and king-sized acquisitions are likely to accelerate in the anti-inflammatory space, as more…
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.